Back to search

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Neoplasms
Clinicaltrials.gov:
EU CTIS:
#2025-520927-26-00
Other:
#78278343PCR3001
Interested in this trial?
Learn more
Email or download this trial
Countries:
  • Australia,
  • Belgium,
  • Brazil,
  • Canada,
  • China,
  • Germany,
  • Italy,
  • Japan,
  • Netherlands,
  • Poland,
  • Puerto Rico,
  • South Korea,
  • Spain,
  • Taiwan,
  • United Kingdom,
  • United States
Loading...
Enrolling
Ghent, Belgium, 9000
Enrolling
Bruges, Belgium, 8000
Enrolling
Porto Alegre, Brazil, 90035 901
Enrolling
Vancouver, British Columbia, Canada, V5Z 4E6
Enrolling
Bay Pines, Florida, United States, 33744
Enrolling
Roanoke, Virginia, United States, 24014
Enrolling
Liège, Belgium, 4000
Enrolling
Québec, Quebec, Canada, G1J 1Z4
Enrolling
Myrtle Beach, South Carolina, United States, 29572
Enrolling
Florianópolis, Brazil, 88034 000
Enrolling
Kaohsiung City, Taiwan, 833
Enrolling
Jeollanam-do, South Korea, 58128
Enrolling
La Louvière, Belgium, 7100
Enrolling
Ottignies, Belgium, 1340
Enrolling
Brussels, Belgium, 1200
Enrolling
Lakewood, Colorado, United States, 80228
Enrolling
Portland, Oregon, United States, 97227
Enrolling
Boston, Massachusetts, United States, 02215
Enrolling
Metairie, Louisiana, United States, 70006
Enrolling
Murdoch, Australia, 6150
Enrolling
Fort Myers, Florida, United States, 33901
Enrolling
Shanghai, China, 200032
Enrolling
Spartanburg, South Carolina, United States, 29303
Enrolling
Greer, South Carolina, United States, 29650
Enrolling
Málaga, Spain, 29010
Enrolling
Madrid, Spain, 28041
Enrolling
Madrid, Spain, 28034
Enrolling
Jerez de la Frontera, Spain, 11407
Enrolling
Kurralta Park, Australia, 5037
Enrolling
Bydgoszcz, Poland, 85 048
Enrolling
Rozzano, Italy, 20089
Enrolling
Kanazawa, Japan, 920 8641
Enrolling
Lancaster, Pennsylvania, United States, 17601
Enrolling
Kobe, Japan, 650 0017
Enrolling
Frankfurt am Main, Germany, 60488
Enrolling
Fukuoka, Japan, 812 8582
Enrolling
Taoyuan District, Taiwan, 333
Enrolling
Houston, Texas, United States, 77030
Enrolling
Hamburg, Germany, 20246
Enrolling
Bala-Cynwyd, Pennsylvania, United States, 19004
Enrolling
New York, New York, United States, 10016
Enrolling
Mineola, New York, United States, 11501
Enrolling
Brooklyn, New York, United States, 11220
Enrolling
Nanjing, China, 210008
Enrolling
Warsaw, Poland, 02 781
Enrolling
Matsuyama, Japan, 791-0280
Enrolling
Meguro Ku, Japan, 152 8902
Enrolling
Taipei, Taiwan, 100
Enrolling
Springfield, Oregon, United States, 97477
Enrolling
Rio Piedras, Puerto Rico, 00935
Enrolling
Melbourne, Australia, 3000
Enrolling
Woolloongabba, Australia, 4102
Enrolling
Hato Rey, Puerto Rico, 00970
Enrolling
Delft, Netherlands, 2625 AD
Enrolling
Aurora, Colorado, United States, 80012
Enrolling
Sutton, United Kingdom, SM2 5PT
Enrolling
Hidaka, Japan, 350 1298
Enrolling
Seoul, South Korea, 06351
Enrolling
Seoul, South Korea, 03722
Enrolling
Taichung, Taiwan, 40705
Enrolling
Taipei, Taiwan, 112
Enrolling
Chattanooga, Tennessee, United States, 37404
Enrolling
Nashville, Tennessee, United States, 37203
Enrolling
Hilversum, Netherlands, 1212 VG
Enrolling
Wichita Falls, Texas, United States, 76310
Enrolling
Manchester, United Kingdom, M20 4BX
Enrolling
Wenzhou, China, 325000
Enrolling
Sakura, Japan, 285-8741
Enrolling
Pittsburgh, Pennsylvania, United States, 15232
Enrolling
London, United Kingdom, WC1E 6BT
Enrolling
Cincinnati, Ohio, United States, 45219
Enrolling
Duisburg, Germany, 47169
Enrolling
Dallas, Texas, United States, 75231
Enrolling
Fairfax, Virginia, United States, 22031
Enrolling
Norfolk, Virginia, United States, 23502
Enrolling
Heidelberg, Australia, 3084
Enrolling
Chengdu, China, 610041
Enrolling
Omaha, Nebraska, United States, 68130
Enrolling
Yokohama, Japan, 236 0004
Enrolling
Yokohama, Japan, 232 0024
Enrolling
Yokosuka, Japan, 238 8558
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Map pin icon representing individual study sites
Individual sites
Access detailed information on the trial:
© Johnson & Johnson and its affiliates 2026
J&J Clinical Trials